Abstract: Xp11 translocation renal cell carcinoma (RCC) are defined by chromosome translocations involving the Xp11 breakpoint which results in one of a variety of TFE3 gene fusions. TFE3 break-apart florescence in situ hybridization (FISH) assays are generally preferred to TFE3 immunohistochemistry (IHC) as a means of confirming the diagnosis in archival material, as FISH is less sensitive to the variable fixation which can result in false positive or false negative IHC. Prompted by a case report in the cytogenetics literature, we identify 3 cases of Xp11 translocation RCC characterized by a subtle chromosomal inversion involving the short arm of the X chromosome, resulting in an RBM10-TFE3 gene fusion. TFE3 rearrangement was not detected by conventional TFE3 break-apart FISH, but was suggested by strong diffuse TFE3 immunoreactivity in a clean background. We then developed novel fosmid probes to detect the RBM10-TFE3 gene fusion in archival material. These cases validate RBM10-TFE3 as a recurrent gene fusion in Xp11 translocation RCC, illustrate a source of false-negative TFE3 break-apart FISH, and highlight the complementary role of TFE3 IHC and TFE3 FISH. X p11 translocation renal cell carcinoma (RCC) encompasses a variety of gene fusions involving TFE3 on Xp11.2 with different gene partners, which triggers oncogenic activation of the TFE3 transcription factor. Known TFE3 fusion partners include ASPSCR1 (ASPL), PRCC, SFPQ1 (PSF), NONO, CLTC, PARP14, LUC7L3, DVL2, and KHSRP. 1-7 Xp11 translocation RCC comprise the majority of pediatric RCC and approximately 1% to 4% of adult RCC. [8] [9] [10] [11] Although a wide range of morphologic appearances have been reported, 12 the most common is that of an RCC with papillary architecture, clear cells, and psammoma bodies. By immunohistochemistry (IHC), these tumors underexpress cytokeratins, but often express melanocytic markers and the cysteine protease cathepsin K, which distinguishes them from more common RCC subtypes. [13] [14] [15] Overall, outcome is similar to that of clear cell RCC; increased age and advanced stage are poor prognostic factors. 16, 17 Immunohistochemistry to detect overexpressed TFE3 fusion proteins using an overnight incubation protocol was shown to be a highly sensitive and specific assay to confirm this diagnosis in formalinfixed, paraffin-embedded archival material 18 ; however, variable fixation (particularly when automated immunostaining techniques are used) significantly reduces the specificity of TFE3 IHC. 19 Break-apart fluorescence in situ hybridization (FISH) assays demonstrating TFE3 gene rearrangement are less affected by variable fixation and now are generally considered the preferred method. 11, 12, 20, 21 Despite recent advances, some RCC displaying clinical, morphologic, and immunohistochemical profiles typical of Xp11 translocation RCC do not demonstrate TFE3 gene rearrangements by FISH. A subset of these prove to be the related t (6;11) translocation RCC resulting in the MALAT1 (Alpha)-TFEB gene fusion, which are grouped together in the current 2016 World Health Organization Classification of Renal Tumors with Xp11 translocation RCC as MiT family translocation RCC. 22, 23 These cases can be detected by TFEB IHC or, preferably, by TFEB break-apart FISH. 24 Nonetheless, some cases with a translocation RCC phenotype remain negative by conventional TFE3 and TFEB FISH assays. One possibility is that these cases demonstrate subtle cytogenetic alterations involving the TFE3 gene at the Xp11.2 locus which are not detectable by FISH resolution. Along these lines, the NONO-TFE3 gene fusion resulting from the intrachromosomal X inversion, inv(X)
X p11 translocation renal cell carcinoma (RCC) encompasses a variety of gene fusions involving TFE3 on Xp11.2 with different gene partners, which triggers oncogenic activation of the TFE3 transcription factor. Known TFE3 fusion partners include ASPSCR1 (ASPL), PRCC, SFPQ1 (PSF), NONO, CLTC, PARP14, LUC7L3, DVL2, and KHSRP. [1] [2] [3] [4] [5] [6] [7] Xp11 translocation RCC comprise the majority of pediatric RCC and approximately 1% to 4% of adult RCC. [8] [9] [10] [11] Although a wide range of morphologic appearances have been reported, 12 the most common is that of an RCC with papillary architecture, clear cells, and psammoma bodies. By immunohistochemistry (IHC), these tumors underexpress cytokeratins, but often express melanocytic markers and the cysteine protease cathepsin K, which distinguishes them from more common RCC subtypes. [13] [14] [15] Overall, outcome is similar to that of clear cell RCC; increased age and advanced stage are poor prognostic factors. 16, 17 Immunohistochemistry to detect overexpressed TFE3 fusion proteins using an overnight incubation protocol was shown to be a highly sensitive and specific assay to confirm this diagnosis in formalinfixed, paraffin-embedded archival material 18 ; however, variable fixation (particularly when automated immunostaining techniques are used) significantly reduces the specificity of TFE3 IHC. 19 Break-apart fluorescence in situ hybridization (FISH) assays demonstrating TFE3 gene rearrangement are less affected by variable fixation and now are generally considered the preferred method. 11, 12, 20, 21 Despite recent advances, some RCC displaying clinical, morphologic, and immunohistochemical profiles typical of Xp11 translocation RCC do not demonstrate TFE3 gene rearrangements by FISH. A subset of these prove to be the related t (6;11) translocation RCC resulting in the MALAT1 (Alpha)-TFEB gene fusion, which are grouped together in the current 2016 World Health Organization Classification of Renal Tumors with Xp11 translocation RCC as MiT family translocation RCC. 22, 23 These cases can be detected by TFEB IHC or, preferably, by TFEB break-apart FISH. 24 Nonetheless, some cases with a translocation RCC phenotype remain negative by conventional TFE3 and TFEB FISH assays. One possibility is that these cases demonstrate subtle cytogenetic alterations involving the TFE3 gene at the Xp11.2 locus which are not detectable by FISH resolution. Along these lines, the NONO-TFE3 gene fusion resulting from the intrachromosomal X inversion, inv(X) (p11.2;q13.1), can be difficult to detect by TFE3 breakapart FISH, often resulting in small constant gaps between the TFE3 signals. 7, 12 Recently, a case report of an Xp11 translocation RCC with fusion between the RBM10 gene at Xp11.23 and TFE3 at Xp11.2 was described in the cytogenetics literature. 25 As RBM10 is located only 1.8 mb apart from TFE3 on the short arm of the X chromosome, the abnormality was difficult to identify by TFE3 break-apart FISH. The gene fusion was confirmed by RNAseq and reverse transcriptase-polymerase chain reaction demonstrating the fusion of RBM10 exon 17 with TFE3 exon 5. This report suggests that RBM10-TFE3 gene fusions could potentially represent the underlying genetic alteration of at least a subset of the group of RCC with a translocation phenotype but which appear to be negative by conventional TFE3 and TFEB FISH. 12 We now report 3 further cases of RBM10-TFE3 RCC. All 3 occurred in adults and were initially reported to be negative for TFE3 rearrangement by FISH.
However, based upon strong morphologic suspicion of Xp11 translocation RCC, strong cathepsin K and TFE3 immunoreactivity, custom fosmid probes were developed to demonstrate the RBM10-TFE3 gene fusion.
MATERIALS AND METHODS

Institutional Review Boards Approval
This study was approved by the Institutional Review Boards at our institutions.
Case Selection and FISH Analysis
The cases studied derive from the consultation files of the authors. Immunohistochemistry was performed as previously described. 7 FISH on interphase nuclei from paraffin-embedded 4-m sections was performed applying custom probes using bacterial artificial chromosomes (BAC) and fosmids, covering and flanking genes of interest. Fosmids are similar to cosmids but utilize the bacterial F-plasmid to allow cleavage of DNA fragments in the range of 35 to 40 kb. TFE3 break-apart FISH was performed as previously described. 12 BAC clones and fosmid clones were chosen according to UCSC genome browser (http://ge nome.ucsc.edu; Supplementary Table 1, Supplemental Digital Content 1, http://links.lww.com/PAS/A479). The BAC and fosmid clones were obtained from BACPAC sources of Children's Hospital of Oakland Research Institute (CHORI) (Oakland, CA) (http://bacpac.chori. org). DNA from individual BACs and fosmids was isolated according to the manufacturer's instructions, labeled with different fluorochromes in a nick translation reaction, denatured, and hybridized to pretreated slides. Slides were then incubated, washed, and mounted with 4 0 , 6-Diamidino-2-Phenylindole in an antifade solution, as previously described. 26 The genomic location of each BAC set was verified by hybridizing them to normal metaphase chromosomes. Two hundred successive nuclei were examined using a Zeiss fluorescence microscope (Zeiss Axioplan, Oberkochen, Germany), controlled by Isis 5 software (Metasystems, Newton, MA). A positive score was interpreted when at least 20% of the nuclei showed a split-apart or come-together signal, depending upon the type of assay applied, either break-apart or fusion assay, respectively. Nuclei with incomplete set of signals were omitted from the score.
RESULTS
Clinical Features and Morphology
All 3 cases occurred in adults. Case 1 was a 61-yearold woman who had a radical nephrectomy for a 3.8 cm pT3 RCC associated with a 3 cm tumor deposit in perirenal adipose tissue, and then developed a peritoneal recurrence 1 year later. Case 2 was a 54-year-old man with a 2.5 cm pT1bNX organ-confined RCC treated by partial nephrectomy. Case 3 was a 45-year-old woman with a 3.8 cm pT1NX organ-confined RCC treated by partial nephrectomy. As the latter 2 cases are recent, no meaningful clinical follow-up is available. All 3 cases demonstrated clear cells and papillary architecture. Case 1 also had prominent solid architecture. Case 2 had prominent psamomma bodies, while case 3 demonstrated focally a second population of smaller cells as has been described previously in both t (6;11) RCC and Xp11 translocation RCC, 12, 23 especially those with the SFPQ-TFE3 gene fusion. 27 Cases 1 and 3 demonstrated foci of subnuclear cytoplasmic vacuolization as often seen in the SFPQ-TFE3 and NONO-TFE3 RCCs. 7 Melanin pigment was not identified in any case. All 3 cases demonstrated diffuse immunoreactivity for cathepsin K and focal labeling for melan A (Figs. 1-3 ). Cytokeratin 7 was negative in all 3 cases; in one of these cases, cytokeratin Cam5.2 and EMA were only focally positive. All 3 cases were initially reported as negative for TFE3 FISH using previously published break-apart probes, 12 and the 2 cases tested (cases 1 and 2) were negative for TFEB rearrangements by break-apart FISH. 24 However, all 3 cases demonstrated diffuse, strong TFE3 labeling by IHC. Therefore, further evaluation was performed to detect the RMB10-TFE3 gene fusion.
RBM10-TFE3 Fusion FISH
As a 1.8 mb chromosomal inversion that would result in an RBM10-TFE3 fusion remains cryptic for the standard FISH resolution using the TFE3 BAC flanking probes, we applied a custom design using 2 fosmid clones covering the most likely breakpoint for each of the RBM10 and TFE3 genes. A positive inversion event was interpreted when each color signal (green for RBM10 and red for TFE3) splits into half-sized pairs, while a negative result revealed nonsplit signals (Fig. 4) . Despite the smaller-sized signals detected using fosmids compared with the more common BACs, all 3 RCC demonstrated a RBM10-TFE3 fusion using this novel assay (Fig. 5) . 
DISCUSSION
We report 3 cases of RBM10-TFE3 RCC. Previously, a single case of an RCC with this gene fusion was reported in the cytogenetics literature. 25 The patient was a 32-year-old woman with a 4.5 cm pT1b RCC with solid, papillary, and trabecular architecture, and epithelioid cells with clear to eosinophilic cytoplasm. The neoplasm was strongly immunoreactive for TFE3 protein by IHC, and the gene fusion was confirmed by RNAseq and reverse transcriptase-polymerase chain reaction demonstrating the fusion of RBM10 exon 17 with TFE3 exon 5. The RMB10-TFE3 gene fusion appears to be a recurrent cytogenetic alteration, as 2 additional RCC cases harboring the RMB10-TFE3 fusion transcript were identified 23 locus) . B, Single color channel assay using the above design for RBM10 in a tumor cell reveals one intact green signal (wild type RBM10 allele, white arrow) and 1 split green signal into 2 half-sized fragments, in keeping with a RMB10 break and inversion event (small gap corresponds to the 1.8 mb distance, blue arrow). C, Similar single color assay for TFE3 showing 1 intact red probe (wild type TFE3 allele, white arrow) and 1 split signal into 2 smaller red fragments pieces (TFE3 break/inversion, blue arrow). D, Two-color fusion assay FISH showing 1 normal sized fused green-red signal due to close proximity of wild type RBM10 and TFE3 genes, and 2 pairs of split-fused smaller signals RBM10 (green) and TFE3 (red) in keeping with the RBM10-TFE3 fusion/inversion. in 2 large sequencing studies of cases characterized as clear cell 28 or papillary 29 RCC, although the details of the clinical, morphologic, and immunohistochemical features of these cases were not provided. Our results confirm the recurrent nature of this cytogenetic alteration, and document that the RBM10-TFE3 RCC have malignant potential, as one of our cases recurred.
Our results also highlight the novel utilization of fosmid probes to detect subtle intrachromosomal inversions that can be missed by standard FISH. Fosmid clones are much smaller (35 to 40 kb) compared with the typical BAC clones (159 to 200 kb) applied in the clinical lab setting, and thus interpretation of fosmid results is less robust, due to their weaker and subtle signals. However, despite the smaller-sized signals, all 3 RCC in our study definitively demonstrated the RBM10-TFE3 gene fusion using this assay. To our knowledge, this technique has not previously been utilized to demonstrate cryptic chromosome inversions and rearrangements in cancer.
Furthermore, our findings illustrate an important pitfall when using TFE3 FISH as the gold standard in diagnosis rather than TFE3 IHC. Although we generally find TFE3 FISH to be more reliable in variably fixed consultation material than TFE3 IHC, 12 and typically use it as the first-line test to evaluate for Xp11 translocation RCC, the RBM10-TFE3 fusion may be missed using the conventional TFE3 break-apart FISH assays. Hence, when we encounter an RCC with a phenotype strongly suggestive of Xp11 translocation RCC (clear cells and papillary architecture, cathepsin K and or melanocytic marker immunoreactivity, conventional TFE3 and TFEB FISH negative), we now routinely perform TFE3 IHC. Strong immunoreactivity for TFE3 in this setting using a properly calibrated assay suggests the possibility of a cryptic rearrangement involving TFE3, and prompts us to evaluate for the RBM10-TFE3 gene fusion. This highlights the importance of utilizing a properly calibrated TFE3 immunohistochemical assay; strong nuclear TFE3 labeling in a clean background is highly suggestive of the rearrangement, while weak or moderate nuclear staining with high background is likely nonspecific as documented previously. 19 Although young patient age makes the diagnosis of translocation RCC more likely, translocation RCC is numerically more common in adults than children due to the much greater overall incidence of RCC in adults, 30 so adult age of the patient should not preclude further work-up. Indeed, all cases of RBM10-TFE3 RCC reported to date (including the 3 in this study) have been in adults.
For pathologists who may not have IHC or FISH for TFE3 or TFEB available, utilization of other more common immunohistochemical markers can help suggest the diagnosis of MiT family translocation RCC. Underexpression of cytokeratins is a useful clue to the diagnosis, 1,2 which can be substantiated by aberrant expression of cathepsin K and/or melanocytic markers. Absence of the latter 2 markers essentially excludes the t (6;11) RCC, but does not exclude Xp11 translocation RCC which will be cathepsin K negative in approximately 50% of cases depending upon fusion type. 7, 14, 15 As our study shows, even a negative conventional TFE3 breakapart FISH study does not exclude the diagnosis of Xp11 translocation RCC, and such cases require more specialized testing for confirmation Finally, we note that the RBM10-TFE3 gene fusion does not account for all renal neoplasms previously described as having a translocation phenotype (ie, RCC with papillary architecture and clear cells that label for cathepsin K by IHC) but for which TFE3 and TFEB FISH assays are negative. 12 We tested 6 additional renal neoplasms with this profile in the course of this study, and none of these 6 were RBM10-TFE3 positive. Three of these 6 cases were strongly positive for TFE3 by IHC (Supplementary Table 2 , Supplemental Digital Content 3, http://links.lww.com/PAS/A481). It is possible that some of these cases harbor other cryptic rearrangements resulting in TFE3 gene fusions that remain to be elucidated. Other such cases likely have different but related genes involved in their pathogenesis, and these genes also remain to be determined.
